23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Inovio Pharmaceuticals, Inc. › 2025-2026

Inovio Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Inovio Pharmaceuticals, Inc.’s Form 8-K, filed May 20, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 11Ballot items
  • 116Asset managers, any item
  • 398Fund votes
  • May 20, 2026Meeting date

Results at a glance

Meeting of May 20, 2026: 11 items on Inovio Pharmaceuticals, Inc.’s Form 8-K, filed May 20, 2026: 11 passed (calculated).

Dissent

No notable dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Ra Capital Management, L.P. (13F, 7.0%, as of September 30, 2026)

Explore Inovio Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Inovio Pharmaceuticals, Inc.

These tallies are Inovio Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 20, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Inovio Pharmaceuticals, Inc. — official shareholder meeting results, meeting held May 20, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Simon X. Benito 22,312,198---- 1,267,18017,091,251 95%Passed (calculated)—
Elect Director: Roger D. Dansey, M.D. 22,480,244---- 1,099,13417,091,251 95%Passed (calculated)—
Elect Director: Ann C. Miller, M.D. 22,544,652---- 1,034,72617,091,251 96%Passed (calculated)—
Elect Director: Jacqueline E. Shea, Ph.D. 22,560,816---- 1,018,56217,091,251 96%Passed (calculated)—
Elect Director: Jay P. Shepard 22,468,210---- 1,111,16817,091,251 95%Passed (calculated)—
Elect Director: David B. Weiner, Ph.D. 22,666,881---- 912,49717,091,251 96%Passed (calculated)—
Elect Director: Wendy L. Yarno 22,451,874---- 1,127,50417,091,251 95%Passed (calculated)—
Elect Director: Lota S. Zoth 22,455,943---- 1,123,43517,091,251 95%Passed (calculated)—
2. The ratification of the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 39,329,5821,198,040143,007 ---- 97%Passed (calculated)—
3. The approval, on a non-binding advisory basis, of the compensation of the NEOs described in the Proxy Statement 21,500,9991,607,592470,787 --17,091,251 93%Passed (calculated)—
4. The approval of the amendment and restatement of the Company's Amended and Restated 2023 Omnibus Incentive Plan as described in the Proxy Statement 21,559,3501,535,940484,088 --17,091,251 93%Passed (calculated)—

This meeting is also recorded here as May 19, 2026; both records come from the same filing, so the date should be checked against it.

Source: Inovio Pharmaceuticals, Inc., Form 8-K, filed with the SEC on May 20, 2026 — read the filing on EDGAR.

How asset managers voted at the Inovio Pharmaceuticals, Inc. 2025-2026 meeting

116 asset managers disclosed a vote on at least one Inovio Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Ann C. Miller, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 22,544,652WITHHELD: 1,034,726

Prior year: 92.2% for (May 20, 2025 meeting) ▲ 3.4 pts

Details: description as filed, official tally, votes by 11 asset managers

Description as filed by funds: To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: Ann C. Miller, M.D.

Inovio Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Ann C. Miller, M.D.”): 22,544,652 for, 1,034,726 withheld, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 11 asset managers below reported 9,861,694 for, 359 withheld, 896 abstained.

FOR
FOR: 9,861,694ABSTAIN: 896WITHHOLD: 359
Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and u” at Inovio Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity9,073,6360 00For
Vanguard720,5730 8960For
BlackRock36,8360 00For
Goldman Sachs10,9310 00For
Equitable7,8270 00For
Victory Capital7,8210 00For
BRIDGEWAY FUNDS INC1,6000 00For
John Hancock1,2570 00For
Blackstone Alternative Investment Funds1,0080 00For
Advisors' Inner Circle Fund III00 0359Withhold
Guggenheim2050 00For

Elect Director: David B. Weiner, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 22,666,881WITHHELD: 912,497

Prior year: 92.4% for (May 20, 2025 meeting) ▲ 3.7 pts

Details: description as filed, official tally, votes by 11 asset managers

Description as filed by funds: To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: David B. Weiner, Ph.D.

Inovio Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: David B. Weiner, Ph.D.”): 22,666,881 for, 912,497 withheld, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 11 asset managers below reported 9,861,694 for, 359 withheld, 896 abstained.

FOR
FOR: 9,861,694ABSTAIN: 896WITHHOLD: 359
Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and u” at Inovio Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity9,073,6360 00For
Vanguard720,5730 8960For
BlackRock36,8360 00For
Goldman Sachs10,9310 00For
Equitable7,8270 00For
Victory Capital7,8210 00For
BRIDGEWAY FUNDS INC1,6000 00For
John Hancock1,2570 00For
Blackstone Alternative Investment Funds1,0080 00For
Advisors' Inner Circle Fund III00 0359Withhold
Guggenheim2050 00For

Elect Director: Jacqueline E. Shea, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 22,560,816WITHHELD: 1,018,562

Prior year: 91.4% for (May 20, 2025 meeting) ▲ 4.3 pts

Details: description as filed, official tally, votes by 11 asset managers

Description as filed by funds: To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: Jacqueline E. Shea, Ph.D.

Inovio Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Jacqueline E. Shea, Ph.D.”): 22,560,816 for, 1,018,562 withheld, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 11 asset managers below reported 9,861,694 for, 359 withheld, 896 abstained.

FOR
FOR: 9,861,694ABSTAIN: 896WITHHOLD: 359
Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and u” at Inovio Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity9,073,6360 00For
Vanguard720,5730 8960For
BlackRock36,8360 00For
Goldman Sachs10,9310 00For
Equitable7,8270 00For
Victory Capital7,8210 00For
BRIDGEWAY FUNDS INC1,6000 00For
John Hancock1,2570 00For
Blackstone Alternative Investment Funds1,0080 00For
Advisors' Inner Circle Fund III00 0359Withhold
Guggenheim2050 00For

Elect Director: Jay P. Shepard

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 22,468,210WITHHELD: 1,111,168

Prior year: 91.0% for (May 20, 2025 meeting) ▲ 4.3 pts

Details: description as filed, official tally, votes by 11 asset managers

Description as filed by funds: To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: Jay P. Shepard

Inovio Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Jay P. Shepard”): 22,468,210 for, 1,111,168 withheld, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 11 asset managers below reported 9,861,694 for, 359 withheld, 896 abstained.

FOR
FOR: 9,861,694ABSTAIN: 896WITHHOLD: 359
Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and u” at Inovio Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity9,073,6360 00For
Vanguard720,5730 8960For
BlackRock36,8360 00For
Goldman Sachs10,9310 00For
Equitable7,8270 00For
Victory Capital7,8210 00For
BRIDGEWAY FUNDS INC1,6000 00For
John Hancock1,2570 00For
Blackstone Alternative Investment Funds1,0080 00For
Advisors' Inner Circle Fund III00 0359Withhold
Guggenheim2050 00For

Elect Director: Lota S. Zoth

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 22,455,943WITHHELD: 1,123,435

Prior year: 92.9% for (May 20, 2025 meeting) ▲ 2.3 pts

Details: description as filed, official tally, votes by 11 asset managers

Description as filed by funds: To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: Lota S. Zoth

Inovio Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Lota S. Zoth”): 22,455,943 for, 1,123,435 withheld, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 11 asset managers below reported 9,861,694 for, 359 withheld, 896 abstained.

FOR
FOR: 9,861,694ABSTAIN: 896WITHHOLD: 359
Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and u” at Inovio Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity9,073,6360 00For
Vanguard720,5730 8960For
BlackRock36,8360 00For
Goldman Sachs10,9310 00For
Equitable7,8270 00For
Victory Capital7,8210 00For
BRIDGEWAY FUNDS INC1,6000 00For
John Hancock1,2570 00For
Blackstone Alternative Investment Funds1,0080 00For
Advisors' Inner Circle Fund III00 0359Withhold
Guggenheim2050 00For

Elect Director: Roger D. Dansey, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 22,480,244WITHHELD: 1,099,134

Prior year: 90.2% for (May 20, 2025 meeting) ▲ 5.2 pts

Details: description as filed, official tally, votes by 11 asset managers

Description as filed by funds: To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: Roger D. Dansey, M.D.

Inovio Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Roger D. Dansey, M.D.”): 22,480,244 for, 1,099,134 withheld, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 11 asset managers below reported 9,861,694 for, 359 withheld, 896 abstained.

FOR
FOR: 9,861,694ABSTAIN: 896WITHHOLD: 359
Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and u” at Inovio Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity9,073,6360 00For
Vanguard720,5730 8960For
BlackRock36,8360 00For
Goldman Sachs10,9310 00For
Equitable7,8270 00For
Victory Capital7,8210 00For
BRIDGEWAY FUNDS INC1,6000 00For
John Hancock1,2570 00For
Blackstone Alternative Investment Funds1,0080 00For
Advisors' Inner Circle Fund III00 0359Withhold
Guggenheim2050 00For

Elect Director: Simon X. Benito

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 22,312,198WITHHELD: 1,267,180

Prior year: 80.7% for (May 20, 2025 meeting) ▲ 13.9 pts

Details: description as filed, official tally, votes by 11 asset managers

Description as filed by funds: To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: Simon X. Benito

Inovio Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Simon X. Benito”): 22,312,198 for, 1,267,180 withheld, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 11 asset managers below reported 9,861,694 for, 359 withheld, 896 abstained.

FOR
FOR: 9,861,694ABSTAIN: 896WITHHOLD: 359
Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and u” at Inovio Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity9,073,6360 00For
Vanguard720,5730 8960For
BlackRock36,8360 00For
Goldman Sachs10,9310 00For
Equitable7,8270 00For
Victory Capital7,8210 00For
BRIDGEWAY FUNDS INC1,6000 00For
John Hancock1,2570 00For
Blackstone Alternative Investment Funds1,0080 00For
Advisors' Inner Circle Fund III00 0359Withhold
Guggenheim2050 00For

Elect Director: Wendy L. Yarno

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 22,451,874WITHHELD: 1,127,504

Prior year: 90.4% for (May 20, 2025 meeting) ▲ 4.8 pts

Details: description as filed, official tally, votes by 11 asset managers

Description as filed by funds: To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: Wendy L. Yarno

Inovio Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Wendy L. Yarno”): 22,451,874 for, 1,127,504 withheld, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 11 asset managers below reported 9,861,694 for, 359 withheld, 896 abstained.

FOR
FOR: 9,861,694ABSTAIN: 896WITHHOLD: 359
Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and u” at Inovio Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity9,073,6360 00For
Vanguard720,5730 8960For
BlackRock36,8360 00For
Goldman Sachs10,9310 00For
Equitable7,8270 00For
Victory Capital7,8210 00For
BRIDGEWAY FUNDS INC1,6000 00For
John Hancock1,2570 00For
Blackstone Alternative Investment Funds1,0080 00For
Advisors' Inner Circle Fund III00 0359Withhold
Guggenheim2050 00For

The approval of the amendment and restatement of the Company's Amended and Restated 2023 Omnibus Incentive Plan as…

Calculated outcomeCOMPENSATIONPassed (calculated)

Combines 2 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 21,559,350AGAINST: 1,535,940

Prior year: 86.9% for (May 20, 2025 meeting) ▲ 6.4 pts

Details: description as filed, official tally, votes by 12 asset managers

Description as filed by funds: TO APPROVE AN AMENDMENT AND RESTATEMENT OF OUR AMENDED AND RESTATED 2023 OMNIBUS INCENTIVE PLAN.

Inovio Pharmaceuticals, Inc.’s own tally for this item (“4. The approval of the amendment and restatement of the Company's Amended and Restated 2023 Omnibus Incentive Plan as described in the Proxy Statement”): 21,559,350 for, 1,535,940 against, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 12 asset managers below reported 9,901,532 for, 1,255 against.

FOR
FOR: 9,901,532AGAINST: 1,255
Largest asset managers voting on “TO APPROVE AN AMENDMENT AND RESTATEMENT OF OUR AMENDED AND RESTATED 2023 OMNIBUS INCENTIVE PLAN.” at Inovio Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity9,073,6360 00For
Vanguard720,573896 00For
Eversept Partners, LP39,8380 00For
BlackRock36,8360 00For
Goldman Sachs10,9310 00For
Equitable7,8270 00For
Victory Capital7,8210 00For
BRIDGEWAY FUNDS INC1,6000 00For
John Hancock1,2570 00For
Blackstone Alternative Investment Funds1,0080 00For
Advisors' Inner Circle Fund III0359 00Against
Guggenheim2050 00For

The approval, on a non-binding advisory basis, of the compensation of the NEOs described in the Proxy Statement

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 21,500,999AGAINST: 1,607,592
Details: description as filed, official tally, votes by 115 asset managers

Description as filed by funds: To approve, on a non-binding advisory basis, the resolution regarding compensation of our named executive officers described in the accompanying proxy statement.

Inovio Pharmaceuticals, Inc.’s own tally for this item (“3. The approval, on a non-binding advisory basis, of the compensation of the NEOs described in the Proxy Statement”): 21,500,999 for, 1,607,592 against, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 12 asset managers voting on “To approve, on a non-binding advisory basis, the resolution regarding compensation of our named executive offi” at Inovio Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity9,073,6360 00For
Vanguard721,4681 00For
BlackRock36,8360 00For
Goldman Sachs10,9310 00For
Equitable7,8270 00For
Victory Capital7,8210 00For
BRIDGEWAY FUNDS INC1,6000 00For
John Hancock1,2570 00For
Blackstone Alternative Investment Funds1,0080 00For
Advisors' Inner Circle Fund III3590 00For
Guggenheim2050 00For
FORUM FUNDS20 00For

Fund voting reports, all 12 managers: 9,862,950 for, 1 against.

Institutional-manager reports: 108 asset managers voting on “To approve, on a non-binding advisory basis, the resolution regarding compensation of our named executive offi” at Inovio Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity8,563,2800 00For
Janus Henderson5,896,3220 00For
Boxer Capital Management, LLC2,120,1220 00For
DE Shaw1,304,6830 00For
ADAR1 Capital Management, LLC1,286,4070 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.804,9580 00For
GEODE CAPITAL MANAGEMENT, LLC668,9040 00For
Two Sigma167,5560 00For
BlackRock104,8940 00For
Northern Trust98,3410 00For
Vanguard80,8590 00For
GMT CAPITAL CORP69,3110 00For
MARSHALL WACE, LLP60,2940 00For
State Street50,3100 00For
CIBC Private Wealth Group LLC50,0000 00For
Green Alpha Advisors, LLC047,404 00Against
GeoWealth Management, LLC37,1470 00For
Goldman Sachs17,9030 00For
STEPHENS INC /AR/15,5000 00For
Renaissance13,3680 00For
683 Capital Management, LLC13,3050 00For
HighTower Advisors, LLC11,1160 00For
PNC BANK, NATIONAL ASSOCIATION8,9580 00For
Victory Capital7,8210 00For
STIFEL NICOLAUS & CO INC \MO\6,3060 00For

Institutional-manager reports, all 108 managers: 21,488,420 for, 54,477 against, 98 not voted. Showing the 25 largest; every one is in the interactive database (link above).

The ratification of the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

97% Majority: yes · of votes cast

FOR 97%
FOR: 39,329,582AGAINST: 1,198,040

Prior year: 97.0% for (May 20, 2025 meeting) ▲ 0.1 pts

Details: description as filed, official tally, votes by 11 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

Inovio Pharmaceuticals, Inc.’s own tally for this item (“2. The ratification of the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 39,329,582 for, 1,198,040 against, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 11 asset managers below reported 9,862,173 for, 776 against.

FOR
FOR: 9,862,173AGAINST: 776
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FI” at Inovio Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity9,073,6360 00For
Vanguard721,052417 00For
BlackRock36,8360 00For
Goldman Sachs10,9310 00For
Equitable7,8270 00For
Victory Capital7,8210 00For
BRIDGEWAY FUNDS INC1,6000 00For
John Hancock1,2570 00For
Blackstone Alternative Investment Funds1,0080 00For
Advisors' Inner Circle Fund III0359 00Against
Guggenheim2050 00For

Largest Inovio Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 82,273,237 shares outstanding at the time of that meeting.

Fund voting reports: top Inovio Pharmaceuticals, Inc. shareholders by shares voted on “To approve, on a non-binding advisory basis, the resolution regarding compensation of our named…”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 11.03%
2Vanguard 0.88%
3BlackRock 0.04%
4Goldman Sachs 0.01%
5Equitable <0.01%
6Victory Capital <0.01%
7BRIDGEWAY FUNDS INC <0.01%
8John Hancock <0.01%
9Blackstone Alternative Investment Funds <0.01%
10Advisors' Inner Circle Fund III <0.01%
Institutional-manager reports: top Inovio Pharmaceuticals, Inc. shareholders by shares voted on “To approve, on a non-binding advisory basis, the resolution regarding compensation of our named…”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 10.41%
2Janus Henderson 7.17%
3Boxer Capital Management, LLC 2.58%
4DE Shaw 1.59%
5ADAR1 Capital Management, LLC 1.56%
6ADAGE CAPITAL PARTNERS GP, L.L.C. 0.98%
7GEODE CAPITAL MANAGEMENT, LLC 0.81%
8Two Sigma 0.20%
9BlackRock 0.13%
10Northern Trust 0.12%

Reported Inovio Pharmaceuticals, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Inovio Pharmaceuticals, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
RA Capital Management, L.P.10,666,523 12.96%Schedule 13G, filed August 7, 2026
FMR (Fidelity)9,339,614 11.35%Form 13F, quarter ended March 31, 2026
HIGHBRIDGE CAPITAL MANAGEMENT LLC6,190,475 7.52%Schedule 13G, filed May 15, 2026
Vanguard Capital Management4,161,566 5.06%Schedule 13G, filed July 31, 2026
Alyeska Investment Group, L.P.4,000,000 4.86%Schedule 13G, filed February 17, 2026
Vanguard Group3,315,580 4.03%Form 13F, quarter ended March 31, 2026
D.E. Shaw2,212,819 2.69%Form 13F, quarter ended March 31, 2026
Millennium Management1,410,845 1.71%Form 13F, quarter ended March 31, 2026
BlackRock662,181 0.80%Form 13F, quarter ended March 31, 2026
Renaissance Technologies643,777 0.78%Form 13F, quarter ended March 31, 2026

Percentages above are of 82,273,237 shares outstanding, as reported by Inovio Pharmaceuticals, Inc. on its Form 10-Q dated May 12, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Inovio Pharmaceuticals, Inc.'s shareholder meeting held May 20, 2026, in the 2025-2026 proxy season, 116 asset managers reported votes on at least one of its 11 ballot items in their SEC Form N-PX filings, covering 398 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the resolution regarding compensation of our named… — FOR was 93% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Inovio Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 20, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Inovio Pharmaceuticals, Inc.’s 10-Q dated May 12, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Inovio Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Inovio Pharmaceuticals (INO) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/inovio-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.